Skip to Content

Generic Bydureon Availability

See also: Generic Bydureon BCise

Bydureon is a brand name of exenatide, approved by the FDA in the following formulation(s):

BYDUREON (exenatide synthetic - for suspension, extended release;subcutaneous)

  • Manufacturer: ASTRAZENECA AB
    Approval date: January 27, 2012
    Strength(s): [RLD]
  • Manufacturer: ASTRAZENECA AB
    Approval date: February 28, 2014
    Strength(s): [RLD]

Has a generic version of Bydureon been approved?

No. There is currently no therapeutically equivalent version of Bydureon available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bydureon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
    Patent 5,424,286
    Issued: June 13, 1995
    Inventor(s): Eng; John
    This invention encompasses pharmaceutical compositions containing exendin-3 or exendin-4, fragments thereof, or any combination thereof, and methods for the treatment of diabetes mellitus and the prevention of hyperglycemia.
    Patent expiration dates:
    • December 1, 2016
      ✓ 
      Patent use: TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
  • C-aryl glucoside SGLT2 inhibitors and method
    Patent 6,414,126
    Issued: July 2, 2002
    Inventor(s): Bruce; Ellsworth & William N.; Washburn & Philip M.; Sher & Gang; Wu & Wei; Meng
    Assignee(s): Bristol-Myers Squibb Company
    SGLT2 inhibiting compounds are provided having the formula where R1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, —OCHF2, —OCF3, halogen, —CN, —CO2R5b, —CO2H, —COR6b, —CH(OH)R6c, —CH(OR5h)R6d, —CONR6R6a, —NHCOR5c, —NHSO2R5d, —NHSO2Aryl, Aryl, —SR5e, —SOR5f, —SO2R5g, —SO2Aryl, or a five, six or seven membered heterocycle, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h and R5i are independently lower alkyl; R6, R6a, R6b, R6c and R6d are independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R6 and R6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH2)n where n is 0-3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
    Patent expiration dates:
    • October 4, 2020
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • October 4, 2020
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Process for the preparation of polymer-based sustained release compositions
    Patent 6,479,065
    Issued: November 12, 2002
    Inventor(s): Warren E.; Jaworowicz & James I.; Wright
    Assignee(s): Alkermes Controlled Therapeutics, Inc.
    The invention relates to a sustained release composition and methods of forming and using said composition for the sustained release of biologically active agent. The sustained release compositions of the invention comprise a biocompatible polymer and a biologically active agent characterized by a porous center and a less porous outer layer wherein the center and outer layer consist of essentially the same materials. The sustained release compositions can be prepared by annealing at least a substantial portion of the exterior surface of a polymer/active agent matrix. The compositions which have been annealed exhibit a decrease in the release of agent over the first 24 hours following administration (i.e., reduced burst) and as a result can show an increase in the duration of sustained release thereby providing increased therapeutic benefits.
    Patent expiration dates:
    • August 10, 2020
      ✓ 
      Drug product
  • Preparation of injectable suspensions having improved injectability
    Patent 6,495,164
    Issued: December 17, 2002
    Inventor(s): J. Michael; Ramstack & M. Gary I.; Riley & Stephen E.; Zale & Joyce M.; Hotz & Olufunmi L.; Johnson
    Assignee(s): Alkermes Controlled Therapeutics, Inc. I
    Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.
    Patent expiration dates:
    • May 25, 2020
      ✓ 
      Drug product
  • C-aryl glucoside SGLT2 inhibitors and method
    Patent 6,515,117
    Issued: February 4, 2003
    Inventor(s): Bruce; Ellsworth & William N.; Washburn & Philip M.; Sher & Gang; Wu & Wei; Meng
    Assignee(s): Bristol-Myers Squibb Company
    An SGLT2 inhibiting compound is provided having the formula A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
    Patent expiration dates:
    • October 4, 2020
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • October 4, 2020
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Preparation of injectable suspensions having improved injectability
    Patent 6,667,061
    Issued: December 23, 2003
    Inventor(s): J. Michael; Ramstack & M. Gary I.; Riley & Stephen E.; Zale & Joyce M.; Hotz & Olufunmi L.; Johnson
    Assignee(s): Alkermes Controlled Therapeutics, Inc.
    Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.
    Patent expiration dates:
    • May 25, 2020
      ✓ 
      Drug product
  • Residual solvent extraction method and microparticles produced thereby
    Patent 6,824,822
    Issued: November 30, 2004
    Inventor(s): Michael E.; Rickey & J. Michael; Ramstack & Rajesh; Kumar
    Assignee(s): Alkermes Controlled Therapeutics Inc. II
    Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.
    Patent expiration dates:
    • October 9, 2022
      ✓ 
      Drug product
  • Methods for regulating gastrointestinal motility
    Patent 6,858,576
    Issued: February 22, 2005
    Inventor(s): Young; Andrew A. & Gedulin; Bronislava & Beeley; Nigel Robert Arnold & Prickett; Kathryn S.
    Assignee(s): Amylin Pharmaceuticals, Inc.
    Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
    Patent expiration dates:
    • January 6, 2017
      ✓ 
      Patent use: REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
  • Methods for glucagon suppression
    Patent 6,872,700
    Issued: March 29, 2005
    Inventor(s): Young; Andrew A. & Gedulin; Bronislava
    Assignee(s): Amylin Pharmaceuticals, Inc.
    Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
    Patent expiration dates:
    • January 14, 2020
      ✓ 
      Patent use: LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
  • C-aryl glucoside SGLT2 inhibitors and method
    Patent 6,936,590
    Issued: August 30, 2005
    Inventor(s): Washburn; William N. & Ellsworth; Bruce & Meng; Wei & Wu; Gang & Sher; Philip M.
    Assignee(s): Bristol Myers Squibb Company
    A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).
    Patent expiration dates:
    • October 4, 2020
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  • Use of exendins for the reduction of food intake
    Patent 6,956,026
    Issued: October 18, 2005
    Inventor(s): Beeley; Nigel Robert Arnold & Bhavsar; Sunil
    Assignee(s): Amylin Pharmaceuticals, Inc.
    Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Patent expiration dates:
    • January 7, 2018
      ✓ 
      Patent use: REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
  • Residual solvent extraction method and microparticles produced thereby
    Patent 7,223,440
    Issued: May 29, 2007
    Inventor(s): Rickey; Michael E. & Ramstack; J. Michael & Kumar; Rajesh
    Assignee(s): Alkermes, Inc.
    Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.
    Patent expiration dates:
    • August 31, 2021
      ✓ 
      Drug product
  • Polymer-based sustained release device
    Patent 7,456,254
    Issued: November 25, 2008
    Inventor(s): Wright; Steven G. & Christenson; Troy & Yeah; Thean Y. & Rickey; Michael E. & Hotz; Joyce M. & Kumar; Rajesh & Costantino; Henry R.
    Assignee(s): Alkermes, Inc.
    This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Patent expiration dates:
    • June 30, 2025
      ✓ 
      Patent use: METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
      ✓ 
      Drug product
  • Polymer-based sustained release device
    Patent 7,563,871
    Issued: July 21, 2009
    Inventor(s): Wright; Steven G. & Christensen; Troy & Yeoh; Thean & Rickey; Michael E. & Hotz; Joyce M. & Kumar; Rajesh & Fineman; Mark & Smith; Christine & Ong; John & Lokensgard; David & Costantino; Henry R.
    Assignee(s): Alkermes, Inc. Amylin Pharmaceuticals, Inc.
    This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Patent expiration dates:
    • April 15, 2024
      ✓ 
      Drug product
  • Polymer-based sustained release device
    Patent 7,612,176
    Issued: November 3, 2009
    Inventor(s): Wright; Steven G. & Christensen; Troy & Yeoh; Thean & Rickey; Michael E. & Hotz; Joyce M. & Kumar; Rajesh & Costantino; Henry R.
    Assignee(s): Alkermes, Inc.
    This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Patent expiration dates:
    • April 13, 2025
      ✓ 
      Patent use: METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
      ✓ 
      Drug product
  • Exendins and exendin agonists for weight reduction and obesity
    Patent 7,741,269
    Issued: June 22, 2010
    Inventor(s): Young; Andrew A. & Bhavsar; Sunil & Gedulin; Bronislava
    Assignee(s): Amylin Pharmaceuticals, Inc.
    Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Patent expiration dates:
    • January 7, 2018
      ✓ 
      Patent use: REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent 7,851,502
    Issued: December 14, 2010
    Inventor(s): Bindra; Dilbir S. & Dali; Mandar V. & Parab; Prakash V. & Patel; Jatin M. & Tao; Li & Tejwani; Ravindra W. & Vatsaraj; Nipa & Wu; Yongmei
    Assignee(s): Bristol-Myers Squibb Company
    Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Patent expiration dates:
    • August 19, 2028
      ✓ 
      Drug product
  • Crystal structures of SGLT2 inhibitors and processes for preparing same
    Patent 7,919,598
    Issued: April 5, 2011
    Inventor(s): Gougoutas; Jack Z. & Lobinger; Hildegard & Ramakrishnan; Srividya & Deshpande; Prashant P. & Bien; Jeffrey T. & Lai; Chiajen & Wang; Chenchi & Riebel; Peter & Grosso; John Anthony & Nirschl; Alexandra A. & Singh; Janak & DiMarco; John D.
    Assignee(s): Bristol-Myers Squibb Company
    The present invention relates to physical crystal structures of a compound of the formula I: wherein R1, R2, R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Patent expiration dates:
    • December 16, 2029
      ✓ 
      Drug substance
  • Administering apparatus with functional drive element
    Patent 8,216,180
    Issued: July 10, 2012
    Inventor(s): Tschirren; Markus & Moser; Ulrich & Hirschel; Juerg & Baumert; Jan & Hattler; Eric
    Assignee(s): TecPharma Licensing AG
    An apparatus for administering a fluid product, including a housing, a product member for accommodating the fluid product and/or a reservoir for the fluid product, which product member can be moved relative to the housing from a start position to an inserted position along a longitudinal axis of the housing, a drive member in the housing and movable relative to the product member for emptying the fluid product from the product member and/or the reservoir, wherein the drive member has at least one holding element which holds the drive member in the start position of the product member and wherein, by the movement of the product member, the holding element is moved from the holding position to a released position in which the drive member is movable relative to the housing.
    Patent expiration dates:
    • January 12, 2028
      ✓ 
      Drug product
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent 8,221,786
    Issued: July 17, 2012
    Inventor(s): Bindra; Dilbir S. & Dali; Mandar V. & Parab; Prakash V. & Patel; Jatin M. & Tao; Li & Tejwani; Ravindra W. & Vatsaraj; Nipa & Wu; Yongmei
    Assignee(s): Bristol-Myers Squibb Company
    Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Patent expiration dates:
    • March 21, 2028
      ✓ 
      Drug product
  • Methods for treating diabetes and reducing body weight
    Patent 8,329,648
    Issued: December 11, 2012
    Inventor(s): Fineman; Mark & MacConell; Leigh & Taylor; Kristin
    Assignee(s): Amylin Pharmaceuticals, LLC
    Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
    Patent expiration dates:
    • August 18, 2026
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent 8,361,972
    Issued: January 29, 2013
    Assignee(s): Bristol Myers-Squibb Company
    Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Patent expiration dates:
    • March 21, 2028
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
    • March 21, 2028
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
  • Polymer-based sustained release device
    Patent 8,431,685
    Issued: April 30, 2013
    Assignee(s): Alkermes Pharma Ireland Limited
    This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Patent expiration dates:
    • April 13, 2025
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES
      ✓ 
      Drug product
  • Device for administering fluid from a multi-chamber ampoule in incremental steps
    Patent 8,439,864
    Issued: May 14, 2013
    Assignee(s): TecPharma Licensing AG
    An administering device for administering an active substance from a multi-chamber container comprising a first chamber holding a solid active substance and a second chamber holding a dissolving liquid for the active substance, wherein the administering device comprises a mixing device for mixing the active substance with the dissolving liquid and a housing accommodating the mixing device, the container being moveable relative to the housing, and the administering device further comprising a first indicator for indicating a position of the container relative to the housing upon completion of a mixing step, and a second indicator for indicating a position of the container relative to the housing upon completion of a venting step.
    Patent expiration dates:
    • March 25, 2028
      ✓ 
      Drug product
  • Polymer-based sustained release device
    Patent 8,461,105
    Issued: June 11, 2013
    Assignee(s): Alkermes Pharma Ireland Limited
    This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Patent expiration dates:
    • April 13, 2025
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES
      ✓ 
      Drug product
  • Crystal structures of SGLT2 inhibitors and processes for preparing same
    Patent 8,501,698
    Issued: August 6, 2013
    Assignee(s): Bristol-Myers Squibb Company
    The present invention relates to physical crystal structures of a compound of the formula I: wherein R1, R2, R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Patent expiration dates:
    • June 20, 2027
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
      ✓ 
      Drug product
  • Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
    Patent 8,685,934
    Issued: April 1, 2014
    Assignee(s): Bristol-Myers Squibb Company
    The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
    Patent expiration dates:
    • May 26, 2030
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
  • Mixing device for a two-chamber ampoule
    Patent 8,690,837
    Issued: April 8, 2014
    Assignee(s): TecPharma Licensing AG
    A device for administering a product (e.g. a medicinal or therapeutic substance), the device including a receptacle for the product or constituents of the product and a casing, wherein the receptacle and casing are engaged, and an outer sleeve, wherein the casing can be moved relative to the receptacle into the outer sleeve.
    Patent expiration dates:
    • May 19, 2029
      ✓ 
      Drug product
  • Artificial engine sound control unit, approaching vehicle audible system, and electric vehicle having them
    Patent 8,712,615
    Issued: April 29, 2014
    Assignee(s): Mitsubishi Electric Corporation
    An artificial engine sound control unit which controls an artificial engine sound which is emitted from a sounding body which is provided at an electric vehicle whose at least a part of drive power is generated by an electric motor, to outside; comprising a speed region determination part which determines a speed region of the electric vehicle and an artificial engine sound generating part, when the speed region determination part determines such that the electric motor of the electric vehicle can be energized and the electric vehicle is stopped, the artificial engine sound generating part controls so as for the sounding body to emit an artificial engine sound, and the artificial engine sound generating part detects such that the electric vehicle comes close to a start running mode, then the artificial engine sound generating part controls the artificial engine sound which is emitted from the sounding body.
    Patent expiration dates:
    • January 18, 2030
      ✓ 
      Drug product
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent 8,716,251
    Issued: May 6, 2014
    Assignee(s): Bristol-Myers Squibb Company
    Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Patent expiration dates:
    • March 21, 2028
      ✓ 
      Drug product
  • Administering apparatus with functional drive element
    Patent 8,758,292
    Issued: June 24, 2014
    Assignee(s): TecPharma Licensing AG
    An apparatus for administering a fluid product, including a housing, a product member for accomodating the fluid product and/or a reservoir for the fluid product, which product member can be moved relative to the housing from a start position to an inserted position along a longitudinal axis of the housing, a drive member in the housing and movable relative to the product member for emptying the fluid product from the product member and/or the reservoir, wherein the drive member has at least one holding element which holds the drive member in the start position of the product member and wherein, by the movement of the product member, the holding element is moved from the holding position to a released position in which the drive member is movable relative to the housing.
    Patent expiration dates:
    • November 12, 2027
      ✓ 
      Drug product
  • Administering device with holding mechanism
    Patent 8,827,963
    Issued: September 9, 2014
    Assignee(s): TecPharma Licensing AG
    An apparatus for administering a substance, e.g. a medicinal, pharmaceutical, or cosmetic substance, includes a driving member movably mounted within the apparatus to administer the substance, and the driving member includes a holding feature or components of a holding feature which holds or retains at least one additional element of the apparatus in a position relative to the apparatus. In some embodiments, the additional element is a carpule or ampoule containing the substance, and the holding feature retains the carpule or ampoule in a position within a carpule or ampoule holder.
    Patent expiration dates:
    • February 4, 2029
      ✓ 
      Drug product
  • Method for treating diabetes
    Patent 8,906,851
    Issued: December 9, 2014
    Assignee(s): Amylin Pharmaceuticals, LLC AstraZeneca Pharmaceuticals LP
    Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
    Patent expiration dates:
    • August 18, 2026
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
  • Ampoule comprising an ampoule holder
    Patent 8,998,876
    Issued: April 7, 2015
    Assignee(s): TecPharma Licensing AG
    An ampoule holder for receiving an ampoule that has a closure element with a radial projection, the ampoule holder including an ampoule seat and a securing member operably coupled to the ampoule seat, wherein the radial projection of the closure element can be arranged between the ampoule seat and securing member.
    Patent expiration dates:
    • January 7, 2030
      ✓ 
      Drug product
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent 9,198,925
    Issued: December 1, 2015
    Assignee(s): AstraZeneca AB
    Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Patent expiration dates:
    • October 4, 2020
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE
    • October 4, 2020
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  • Polymer-based sustained release device
    Patent 9,238,076
    Issued: January 19, 2016
    Assignee(s): Alkermes Pharma Ireland Limited Amylin Pharmaceuticals, LLC
    This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Patent expiration dates:
    • April 15, 2024
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES
      ✓ 
      Drug product
  • Method for administering a fluid active substance from a multi-chamber ampoule
    Patent 9,320,853
    Issued: April 26, 2016
    Assignee(s): TecPharma Licensing AG
    An administering device for administering an active substance from a multi-chamber container comprising a first chamber holding a solid active substance and a second chamber holding a dissolving liquid for the active substance, wherein the administering device comprises a mixing device for mixing the active substance with the dissolving liquid and a housing accommodating the mixing device, the container being moveable relative to the housing, and the administering device further comprising a first indicator for indicating a position of the container relative to the housing upon completion of a mixing step, and a second indicator for indicating a position of the container relative to the housing upon completion of a venting step.
    Patent expiration dates:
    • March 25, 2028
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 24, 2018 - INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
    • October 20, 2020 - INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide